Spectrum and TopoTarget in US$350 M Deal for Belinostat
By Taskin Ahmed
PharmaDeals Review: Vol 2010 Issue 2 (Table of Contents)
Published: 5 Feb-2010
DOI: 10.3833/pdr.v2010i2.1308 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Spectrum Pharmaceutical is paying US$30 M upfront for TopoTarget’s Phase III lymphoma drug, belinostat, a histone deacetylase (HDAC) inhibitor in development for the treatment of peripheral T cell lymphoma (PTCL)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS